Zogenix, Inc. ZGNX, a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain, announced today
preliminary unaudited gross product sales for the quarter ended December 31,
2012. Zogenix expects to report fourth quarter 2012 gross product sales of
approximately $13.5 million on 145,200 units shipped, with unit volume up
approximately 9% sequentially from third quarter 2012 and 26% from fourth
quarter 2011.
For the full year 2012, Zogenix announced preliminary unaudited net product
revenue of approximately $36 million, up approximately 18% over 2011 and
slightly below previously issued guidance of $37 million for 2012.
Preliminary unaudited cash and cash equivalents as of December 31, 2012 were
approximately $41.2 million.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in